If my take on it is correct the VenusIII results reflect those expected from the placebo (SC).
If that is incorrect disregard below!!
VenusIII (n=49) .......................... VF00102 (n=113)
week 12 ......... 41% fully healed ............................. ~50% fully healed
week 4......... 25% wound reduction ....................... 50%wound reduction
week 10........ 50% wound reduction ....................... 68% wound reduction
week 12 ...... 55% wound reduction ........................ 70% wound reduction
(Italics means measured from published curve Bioshares presentation)
So the Venus III results, or very similar, would be expected to be embedded in the VF00102 interim results.
Looking at week 12.......taking account of the fully healed to get stated average wound reduction values, the average wound reduction of those not fully healed would be 24% VIII and 40% VF.
Looking quite nice to me so far.
- Forums
- ASX - By Stock
- Ann: CEO Presentation to Bioshares Conference
If my take on it is correct the VenusIII results reflect those...
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable